MBP and chronic myelogenous leukemia, BCR-ABL1 positive: EFS was not significantly different between patients who received a TSR vs. “7 + 3” chemotherapy (11.1% vs. 33.3% at 1-year; P = 0.53), ponatinib vs. dasatinib (16.7% vs. 25% at 1-year; P = 0.72), or patients who presented with progressed vs. de novo CML-MBP (16.7% vs. 25% at 1-year; P = 0.23) (Fig. 3a and c).